BRIEF-Pfizer’s Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis

Reuters03-09
BRIEF-Pfizer’s Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis

March 9 (Reuters) - Pfizer Inc PFE.N:

  • PFIZER’S PHASE 2 STUDY OF TRISPECIFIC ANTIBODY POSITIVE IN MODERATE TO SEVERE ATOPIC DERMATITIS

  • PFIZER - PHASE 2 STUDY MET PRIMARY ENDPOINT WITH STATISTICALLY SIGNIFICANT EASI-75 AT WEEK 16

  • PFIZER: STUDY MET PRIMARY ENDPOINT,

  • PFIZER - TILREKIMIG (PF-07275315) WELL-TOLERATED WITH FAVORABLE SAFETY PROFILE

  • PFIZER - PLANS TO ACCELERATE TILREKIMIG TO PHASE 3 WITH PIVOTAL STUDY STARTING THIS YEAR

  • PFIZER - ALSO STUDYING TILREKIMIG IN PHASE 2 STUDY IN ASTHMA

Source text: ID:nBwbdr4kta

Further company coverage: PFE.N

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment